Progressive Clinical Research PA

1. AbbVie, Inc. $736,223 160 payments
2. Boehringer Ingelheim Pharmaceuticals, Inc. $100,130 3 payments
3. Padagis US LLC $47,230 4 payments
4. Amgen Inc. $22,666 5 payments
5. Journey Medical Corporation $11,000 2 payments
6. Vanda Pharmaceuticals Inc. $3,000 1 payment
7. Ucb SA $532 2 payments
8. UCB Biosciences Inc. $480 1 payment

1. Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis $140,884 17 payments
2. M16-766 $100,925 15 payments
3. Phase IIa study in patients with atopic dermatitis $100,130 3 payments
4. A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) $85,482 17 payments
5. A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) $80,845 18 payments
6. A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) $72,012 9 payments
7. M16-047 $66,444 19 payments
8. M15-997 $54,132 18 payments
9. A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Padagis Israel Pharmaceuticals, Ltd. Roflumilast Cream 0.3% to Arcutis Biotherapeutics, Inc. Zoryve (Roflumilast Cream 0.3%) Cream and Both Active Treatments to a Vehicle Control in the Treatment of Plaque Psoriasis $47,230 4 payments
10. M15-999 $33,307 10 payments

1. Patient care $11,000 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.